ArticleThe American journal of tropical medicine and hygiene2025
Disseminated Cutaneous Leishmaniasis Caused by Leishmania major in Immunocompetent Sudanese Child.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmania major is the predominant cause of cutaneous leishmaniasis (CL) in Sudan. The disease frequently presents as localized skin lesions that usually heals spontaneously. A 10-year-old girl from Darfur, presented to Khartoum Dermatology Hospital with a 1-year history of widespread skin lesions. The lesions began as small papules on her upper and lower limbs and progressively involved all exposed areas, including her face, over 5 months. Diagnosis was confirmed by parasitology and culture from lesions aspirates. Leishmania major was identified by polymerase chain reaction. The patient was initially treated with intramuscular sodium stibogluconate (10 mg/kg) for 1 month, with no significant improvement. Subsequently, intravenous liposomal amphotericin B (Ambisome) was administered at a dose of 2.5 mg/kg daily in dextrose 5% for 14 days. Marked clinical improvement was observed, with lesions beginning to heal. Treatment was extended for an additional 40 days. The patient showed full recovery, with healed lesions leaving scars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.